Clinical Trial: To evaluate the efficacy, safety and adverse reactions of "TAE combined with hepatic arterial infusion of tislelizumab + bevacizumab" as the first-line treatment for hepatocellular carcinoma (China)

China, Aug. 19 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'To evaluate the efficacy, safety and adverse reactions of "TAE combined with hepatic arterial infusion of tislelizumab + bevacizumab" as the first-line treatment for hepatocellular carcinoma'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130329

Registration Time: 2026/08/18

Type: Interventional study

Primary Sponsor: Ziyang Central Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=262586

Published by HT Digital Content Services with permission from Health Daily Digest....